Risk factors for peripheral venous catheter failure: A prospective cohort study of 5345 patients

Ya-mei Chen1*, Xiao-wen Fan2*, Ming-hong Liu3, Jie Wang4, Yi-qun Yang4 and Yu-fang Su5

Abstract
Purpose: The objective of this study was to determine the independent risk factors associated with peripheral venous catheter (PVC) failure and develop a model that can predict PVC failure.
Methods: This prospective, multicenter cohort study was carried out in nine tertiary hospitals in Suzhou, China between December 2017 and February 2018. Adult patients undergoing first-time insertion of a PVC were observed from catheter insertion to removal. Logistic regression was used to identify the independent risk factors predicting PVC failure.
Results: This study included 5345 patients. The PVC failure rate was 54.05% (n = 2889/5345), and the most common causes of PVC failure were phlebitis (16.3%) and infiltration/extravasation (13.8%). On multivariate analysis, age (45–59 years: OR, 1.295; 95% CI, 1.074–1.561; 60–74 years: OR, 1.375; 95% CI, 1.143–1.654; ≥75 years: OR, 1.676; 95% CI, 1.355–2.073); department (surgery OR, 1.229; 95% CI, 1.062–1.423; emergency internal/surgical ward OR, 1.451; 95% CI, 1.082–1.945); history of venous puncture in the last week (OR, 1.298, 95% CI 1.130–1.491); insertion site, number of puncture attempts, irritant fluid infusion, daily infusion time, daily infusion volume, and type of sealing liquid were independent predictors of PVC failure. Receiver operating characteristic curve analysis indicated that a logistic regression model constructed using these variables had moderate accuracy for the prediction of PVC failure (area under the curve, 0.781). The Hosmer-Lemeshow goodness of fit test demonstrated that the model was correctly specified (χ² = 2.514, p = 0.961).
Conclusion: This study should raise awareness among healthcare providers of the risk factors for PVC failure. We recommend that healthcare providers use vascular access device selection tools to select a clinically appropriate device and for the timely detection of complications, and have a list of drugs classified as irritants or vesicants so they can monitor patients receiving fluid infusions containing these drugs more frequently.

Keywords
Peripheral venous catheter, complication, risk factors, prediction model

Date received: 24 November 2020; accepted: 10 April 2021

*These authors contributed equally to this work.

Corresponding authors:
Yi-qun Yang, Department of Nursing, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215006, China. Email: 592436680@qq.com
Yu-fang Su, Department of Orthopaedic, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou 215006, China. Email: 1007013607@qq.com
Introduction

Peripheral venous catheter (PVC) is commonly used to obtain short-term venous access and administer invasive procedures performed by healthcare providers. Although PVC has widespread use, an estimated 26%–69% of PVCs fail mainly due to complications such as phlebitis, occlusion, dislodgement, infiltration/extravasation, and local infection. PVC failure is associated with interruption of treatment, catheter replacements, infection and mortality, and can increase length of hospital stay and healthcare costs. Therefore, there remains an unmet clinical need to identify the risk factors associated with PVC failure and prevent catheter complications.

Previous studies have confirmed that patient age, catheter type, insertion site, puncture technique, and chronic disease affect the incidence of PVC failure. However, these studies were limited by small sample size and their retrospective design, which may bias the results. In addition, predictive models of PVC failure in adult patients are scarce. A prediction model will facilitate early identification of PVC failure, enable timely intervention, and reduce the clinical and economic burden of catheter complications.

The objective of this study was to determine the independent risk factors associated with PVC failure and develop a model that can predict PVC failure. This model may have clinical utility for early identification of PVC failure.

Methods

Study design, and participants

The study design is shown in Figure 1. Patients who were hospitalized in nine tertiary hospitals in Suzhou, China between December 2017 and February 2018 were eligible to participate in this prospective multicenter cohort study. Inclusion criteria were (1) aged ≥18 years and (2) undergoing first-time insertion of a PVC. Exclusion criteria were (1) insertion of another vascular access device into the same limb or (2) insertion of a PVC before admission. All patients provided written informed consent.

Sampling and sample size

This study used cluster sampling. The following formula was used to calculate the required sample size: 
\[ n = \frac{\mu^2 \cdot \sigma^2}{\alpha^2 \cdot P(1-P) / \delta^2} \]

where \( n \) is the sample size, \( \mu \) is the population mean, \( \alpha \) is the Type I error probability, \( P \) is the estimated PVC failure rate, and \( \delta \) is the allowable error. Assuming that 26% of PVCs fail, the calculated sample size was 1094. Considering a loss to follow up rate of 20%, the sample size for this study was 1313.

Data collection

Patient recruitment and data collection were performed by nurses. Data were organized and recorded by liaison officers. The lead author trained the nurses and liaison officers, supervised compliance with the study protocol, confirmed data integrity, and performed data analysis. All insertion, maintenance, and removal of PVCs were performed by qualified nurses, in accordance with standardized procedures.

Data collection included patient baseline demographic and clinical characteristics, such as age, gender, department, admitting diagnosis and comorbidities, and catheter related-information such as insertion site, irritant infusion, securement method, dressing type, infusion regimen, daily infusion time, and causes of PVC failure. The insertion site was evaluated at shift change or if there were signs of PVC failure. The PVC was removed at the end of treatment, due to complications, or 72–96 h after insertion.

PVC failure was defined as catheter removal for any reason other than exceeding the maximum indwelling time or completion of infusion therapy. Reasons for PVC failure included, but were not limited to, phlebitis, infiltration/extravasation, occlusion, dislodgement, or leakage from the insertion site. Phlebitis was assessed using the Infusion Nurses Society (INS) phlebitis scale. Infiltration/extravasation was defined as leakage of an irritant or vesicant from the blood vessels to surrounding tissues. Occlusion was defined as the inability to infuse intravenous fluids. Leakage from the insertion site was defined as inadvertent leakage of intravenous fluids from the insertion site. Dislodgement was defined as accidental removal or movement of the device that resulted in loss of function.

Statistical analysis

Data were analyzed using SPSS18.0 statistical software. Normally distributed data are reported as mean and standard deviation. Non-normally distributed data are reported as medians and interquartile ranges. Categorical data are reported as frequencies and proportions. The frequency of PVC failure was calculated. Univariate and multivariate logistic regression analyses were used to determine predictors of PVC failure. Univariate analysis used the chi-square test. Statistically significant variables (\( p < 0.05 \)) were included in the multivariate analysis. Odds ratios (OR) and their corresponding 95% confidence intervals (CI) were calculated. Statistically significant variables were used to establish a predictive model. Receiver operating characteristic curve (ROC), area under the curve (AUC; where 0.5 = chance result; 0.5–0.7 = low accuracy; 0.7–0.9 = moderate accuracy; 0.9 = high accuracy), and the Hosmer-Lemeshow goodness of fit test were used to evaluate model performance.
Figure 1. Flow chart of study design.
Results

This study included 5345 patients hospitalized on wards associated with the following departments: internal medicine (digestive, respiratory, cardiology, neurology), surgery (general surgery, orthopedics, thoracic surgery, neurosurgery) and obstetrics and gynecology, and on an emergency internal/surgical ward that included patients with acute pancreatitis, gastrointestinal bleeding, pulmonary infection, multiple trauma, and cerebral hemorrhage.

Patient baseline demographic and clinical characteristics are summarized in Table 1. Median age of included patients was 59 years (range, 18–102), and 46.4% (2481) of patients were male. Most patients were hospitalized on internal medicine wards (2081, 38.9%) and surgery wards (2144, 40.1%). 31.4% (n=1680) of the patients had hypertension and diabetes.

Reasons for PVC failure are summarized in Table 2. The PVC failure rate was 54.05% (n=2889/5345). The most common causes of PVC failure were phlebitis (16.3%) and infiltration/extravasation (13.8%).

Multivariate analysis

Multivariate analysis of predictors of PVC failure are summarized in Table 3. On multivariate analysis, age (45–59 years: OR, 1.295; 95% CI, 1.074–1.561; 60–74 years: OR, 1.375; 95% CI, 1.143–1.654; ≥75 years: OR, 1.676; 95% CI, 1.355–2.073), department (surgery OR, 1.229; 95% CI, 1.062–1.423; emergency internal/surgical ward OR, 1.451; 95% CI, 1.082–1.945), history of venous puncture in the last week (OR, 1.201; 95% CI, 1.045–1.380), number of puncture attempts (>2: OR, 1.317; 95% CI, 1.025–1.693), irritant fluid infusion (OR, 1.344, 95% CI, 1.148–1.574), daily infusion time (4–6 h: OR, 1.513; 95% CI, 1.264–1.810; >6 h: OR, 1.868; 95% CI 1.479–2.359), daily infusion volume (501–1000 ml, and use of heparinized saline as the sealing liquid. ROC curve analysis indicated that the logistic regression model constructed using these variables had moderate accuracy for the prediction of PVC failure, while the Hosmer-Lemeshow goodness of fit test demonstrated that the model was correctly specified.

Previous reports have described lower rates of PVC failure than the 54.05% reported in our study. Specifically, catheter failure occurred in 31% of patients with emergency department (ED)-inserted PVCs admitted to hospital wards in two large academically affiliated hospitals in Perth, Western Australia and in 32% of adult patients requiring a PVC on the medical and surgical wards of a tertiary hospital in Queensland, Australia. The disparate results between our study and the previous studies may be related to differences in the included patient populations. In the present study, almost 50% of the patients were aged ≥60 years; therefore, vascular aging, which affects vascular stiffness and permeability, may have contributed to the high incidence of PVC failure.

In our study, the most common causes of PVC failure were phlebitis (16.3%) and infiltration/extravasation (13.8%). The incidence of phlebitis was lower than previous reports of PVC-related phlebitis in adult patients in tertiary hospitals in Croatia (44%) or in patients treated as urgent cases in EDs in Italy (31%). Differences in the findings from our study and the previous studies may be attributed to differences in the characteristics of the patient populations or healthcare settings in which they were conducted, and the lack of a concensus definition and standard assessment tool for phlebitis, which makes diagnosis of phlebitis a challenge.

Our study identified several factors as predictors of PVC failure in adult patients. Specifically, findings showed that the risk of PVC failure increased with increasing patient age. Consistent with these data, the risk of PVC failure was associated with being an older patient in the
Table 1. Patient baseline demographic and clinical characteristics.

| Variable                        | PVC failure | Overall (N=5345) | \(\chi^2\) | p       | OR (95% CI) |
|---------------------------------|-------------|------------------|------------|---------|-------------|
|                                 | Yes (N=2889; 54.05), No. (%) | No (N=2456; 45.95), No. (%) |            |         |             |
| **Gender**                      |             |                  |            |         |             |
| Male                            | 1363 (47.2) | 1118 (45.5)      | 2481 (46.4) | 1.467   | 0.226       |
| Female                          | 1526 (52.8) | 1338 (54.5)      | 2864 (53.6) | 1.069   | (0.960, 1.191) |
| **Age**                         |             |                  |            |         |             |
| ⩽44                             | 729 (25.2)  | 789 (32.1)       | 1518 (28.4) | 35.024  | <0.001      |
| 45–59                           | 670 (23.2)  | 533 (21.8)       | 1203 (22.5) | 1.360   | (1.169, 1.584) |
| 60–74                           | 902 (31.2)  | 728 (29.6)       | 1630 (30.5) | 1.341   | (1.165, 1.543) |
| ⩾75                             | 588 (20.4)  | 406 (16.5)       | 994 (18.6)  | 1.567   | (1.334, 1.843) |
| **Department**                  |             |                  |            |         |             |
| Internal medicine               | 1071 (37.1) | 1010 (41.1)      | 2081 (38.9) | 102.255 | <0.001      |
| Surgery                         | 1284 (44.4) | 860 (35.0)       | 2144 (40.1) | 1.408   | (1.246, 1.590) |
| Obstetrics and gynecology       | 334 (11.6)  | 476 (19.4)       | 810 (15.2)  | 0.662   | (0.562, 0.780) |
| Emergency internal/surgical ward| 200 (6.9)   | 110 (4.5)        | 310 (5.8)   | 1.715   | (1.338, 2.197) |
| **Comorbidities**               |             |                  |            |         |             |
| No                              | 1947 (67.4) | 1703 (69.3)      | 3650 (68.3) | 2.782   | 0.595       |
| Diabetes                        | 139 (4.8)   | 111 (4.5)        | 250 (4.7)   | 1.095   | (0.846, 1.417) |
| Hypertension                    | 184 (25.0)  | 522 (21.3)       | 1183 (22.1) | 1.108   | (0.971, 1.264) |
| Diabetes and hypertension       | 661 (22.9)  | 114 (4.6)        | 247 (4.6)   | 1.020   | (0.788, 1.321) |
| Other                           | 9 (0.3)     | 6 (0.3)          | 15 (0.3)    | 1.312   | (0.466, 3.694) |
| History of venous puncture for nearly 1 week | 1962 (67.9) | 1809 (73.7) | 3771 (70.6) | 21.078 | <0.001      |
| Yes                             | 927 (32.1)  | 647 (26.3)       | 1574 (29.4) | 1.321   | (1.173, 1.488) |
| **Catheter type**               |             |                  |            |         |             |
| Closed normal type              | 2025 (70.1) | 1705 (69.4)      | 3730 (69.8) | 8.092   | 0.017       |
| Closed safety type              | 814 (28.2)  | 680 (27.7)       | 1494 (28.0) | 1.008   | (0.893, 1.137) |
| Open type                       | 50 (1.7)    | 71 (2.9)         | 121 (2.3)   | 0.593   | (0.411, 0.856) |
| **Infusion tap type**           |             |                  |            |         |             |
| Heparin lock                    | 2729 (94.5) | 2354 (95.8)      | 5083 (95.1) | 5.464   | 0.019       |
| Needleless connector            | 160 (5.5)   | 102 (4.2)        | 262 (4.9)   | 1.353   | (1.049, 1.745) |
| **Gauge**                       |             |                  |            |         |             |
| 24 g                            | 2038 (70.5) | 1648 (67.1)      | 3686 (69.0) | 7.369   | 0.025       |
| 22 g                            | 712 (24.6)  | 674 (27.4)       | 1386 (25.9) | 0.854   | (0.755, 0.967) |
| 18–20 g                         | 139 (4.8)   | 134 (5.5)        | 273 (5.1)   | 0.839   | (0.656, 1.073) |
| **Insertion site**              |             |                  |            |         |             |
| Back of hand                    | 1425 (49.3) | 1352 (55.0)      | 2777 (52.0) | 23.102  | <0.001      |
| Wrist                           | 229 (7.9)   | 199 (8.1)        | 428 (8.0)   | 1.092   | (0.890, 1.339) |
| Forearm                         | 1123 (38.9) | 834 (34.0)       | 1957 (36.6) | 1.278   | (1.137, 1.435) |
| Antecubital fossa               | 70 (2.4)    | 52 (2.1)         | 122 (2.3)   | 1.277   | (0.885, 1.842) |
| Other                           | 42 (1.5)    | 19 (0.8)         | 61 (1.1)    | 2.097   | (1.214, 3.624) |
| **Number of puncture attempts** |             |                  |            |         |             |
| 1                               | 2662 (92.1) | 2322 (94.5)      | 4984 (93.2) | 12.155  | <0.001      |
| ⩾2                             | 227 (7.9)   | 134 (5.5)        | 361 (6.8)   | 1.478   | (1.185, 1.842) |
| **Securement regimen**          |             |                  |            |         |             |
| Transparent dressings           | 2869 (99.3) | 2429 (98.9)      | 5298 (99.1) | 3.098   | 0.377       |
| Gauze + adhesive tape           | 8 (0.30)    | 10 (0.40)        | 18 (0.3)    | 0.677   | (0.267, 1.719) |
| Disposable wound dressing       | 1 (0.10)    | 3 (0.10)         | 4 (0.1)     | 0.282   | (0.029, 2.715) |
| Transparent dressings + gauze   | 11 (0.40)   | 14 (0.60)        | 25 (0.5)    | 0.665   | (0.301, 1.468) |
| **Dressing type**               |             |                  |            |         |             |
| Ordinary                        | 1225 (42.4) | 778 (31.7)       | 2003 (37.5) | 65.164  | <0.001      |
| Reinforced                      | 1664 (57.6) | 1678 (68.3)      | 3342 (62.5) | 0.630   | (0.563, 0.705) |

(Continued)
Table 1. (Continued)

| Variable                        | PVC failure | Overall | \( \chi^2 \) | \( p \) | OR (95% CI) |
|--------------------------------|-------------|---------|--------------|-------|-------------|
|                                | Yes (N=2889; 54.05), No. (%) | No (N=2456; 45.95), No. (%) |              |       |             |
| Irritant fluid infusion        |             |         |              |       |             |
| No                             | 2027 (70.2) | 2016 (82.1) | 4043 (75.6) | 102.402 | <0.001 | — |
| Yes                            | 862 (29.8) | 440 (17.9) | 1302 (24.4) |         | 1.948 (1.710, 2.220) |
| Infusion apparatus type        |             |         |              |       |             |
| Ordinary                       | 2059 (71.3) | 1753 (71.4) | 3812 (71.3) | 0.007 | 0.932 | — |
| Precise                        | 830 (28.7) | 703 (28.6) | 1533 (28.7) |         | 1.005 (0.892, 1.132) |
| Infusion regimen               |             |         |              |       |             |
| Intermittent therapy           | 2799 (96.9) | 2410 (98.1) | 5209 (97.5) | 8.262 | 0.004 | — |
| Continuous therapy             | 90 (3.1) | 46 (1.9) | 136 (2.5) |         | 1.685 (1.176, 2.413) |
| Daily infusion time            |             |         |              |       |             |
| <4 h                           | 750 (26.0) | 1029 (41.9) | 1779 (33.3) | 163.160 | <0.001 | — |
| 4–6 h                          | 1275 (44.1) | 930 (37.9) | 2205 (41.3) |         | 1.881 (1.657, 2.135) |
| >6 h                           | 781 (27.0) | 455 (18.5) | 1236 (23.1) |         | 2.355 (2.029, 2.734) |
| Daily infusion volume          |             |         |              |       |             |
| ≤500                           | 695 (24.1) | 944 (38.4) | 1629 (30.7) | 141.49 | <0.001 | — |
| 501–1000                       | 1262 (43.7) | 950 (38.7) | 2212 (41.4) |         | 1.804 (1.586, 2.053) |
| 1001–1500                      | 498 (17.2) | 323 (13.2) | 821 (15.4) |         | 2.094 (1.765, 2.484) |
| >1500                          | 434 (15.0) | 239 (9.7) | 673 (12.6) |         | 2.466 (2.048, 2.970) |
| Flushing before infusion       |             |         |              |       |             |
| No                             | 59 (2.0) | 4 (0.2) | 63 (1.2) | 40.254 | <0.001 | — |
| Yes                            | 2830 (98.0) | 2452 (99.8) | 5282 (98.8) |         | 0.078 (0.028, 0.216) |
| Flushing fluid                 |             |         |              |       |             |
| Saline                         | 2745 (95.0) | 2377 (96.8) | 5122 (95.8) | 40.267 | <0.001 | — |
| Heparin saline                 | 85 (2.9) | 75 (3.1) | 160 (3.0) |         | 0.981 (0.716, 1.345) |
| Flushing fluid volume          |             |         |              |       |             |
| ≤5                             | 2707 (93.7) | 2363 (96.2) | 5070 (94.9) | 42.007 | <0.001 | — |
| >5                             | 123 (4.3) | 89 (3.6) | 212 (4.0) |         | 1.206 (0.913, 1.593) |
| Sealing regimen                |             |         |              |       |             |
| Positive pressure sealing tube  | 2833 (98.1) | 2456 (100.0) | 5289 (99.0) | 69.412 | <0.001 | — |
| Use positive pressure connector without sealing tube | 55 (1.9) | 0 (0.0) | 55 (1.0) |         | 0.000 |
| Sealing liquid                 |             |         |              |       |             |
| Saline                         | 2736 (94.7) | 2408 (98.0) | 5144 (96.2) | 58.343 | <0.001 | — |
| Heparin saline                 | 98 (3.4) | 48 (2.0) | 146 (2.7) |         | 1.797 (1.267, 2.549) |
| Sealing liquid volume          |             |         |              |       |             |
| ≤5                             | 2751 (95.2) | 2379 (96.9) | 5130 (96.0) | 47.434 | <0.001 | — |
| >5                             | 83 (2.9) | 77 (3.1) | 160 (3.0) |         | 0.932 (0.680, 1.277) |
| Indwelling time                |             |         |              |       |             |
| t=≤24 h                        | 529 (18.3) | 165 (6.7) | 694 (13.0) | 873.388 | <0.001 | — |
| 24 h < t ≤ 48 h                | 1001 (34.6) | 332 (13.5) | 1333 (25.0) |         | 0.940 (0.759, 1.165) |
| 48 h < t ≤ 72 h                | 896 (31.0) | 720 (29.3) | 1616 (30.2) |         | 0.388 (0.318, 0.474) |
| 72 h < t ≤ 96 h                | 328 (11.4) | 936 (38.2) | 1264 (23.6) | 0.109 (0.088, 0.136) |
| t > 96 h                       | 135 (4.7) | 303 (12.3) | 438 (8.2) |         | 0.139 (0.106, 0.182) |

study of patients with ED-inserted PVCs conducted in Western Australia. Age-related impairment of vascular structure and function may lead to vascular stiffness, endothelial dysfunction, and hypoperfusion. Our results also revealed that department was an independent predictor of PVC failure, whereby patients hospitalized on the surgery or emergency internal/surgical ward, mostly suffering from acute pancreatitis, gastrointestinal bleeding, pulmonary infection, multiple trauma, or cerebral hemorrhage, were more likely to experience PVC failure than patients hospitalized on other wards. In accordance with these findings, PVC failure was significantly associated with department (internal medicine, general surgery, orthopedics, gynecology, other surgery) in a previous
Table 2. Causes of PVC failure.

| Reasons for PVC failure | N   | % of Total (n = 5345) |
|-------------------------|-----|-----------------------|
|                         |     | % F (n = 2889)        |
| Phlebitis               | 873 | 16.3                  |
| Infiltration/extravasation | 737 | 13.8                  |
| Occlusion               | 654 | 12.2                  |
| Local liquid leakage    | 362 | 6.8                   |
| Dislodgement            | 36  | 0.7                   |
| Changed to CVC          | 55  | 0.1                   |
| Prevention of complications | 84  | 1.6                   |
| Patient’s request       | 69  | 1.3                   |
| Operation               | 19  | 0.4                   |

Reasons for PVC removal

| Reasons for PVC removal | N   | % PIVC removal (n = 2456) |
|-------------------------|-----|---------------------------|
| No longer required      | 1521| 28.5                      |
| Routine removal at 72 h  | 935 | 17.5                      |

CVC: central venous catheter.

Table 3. Logistic regression analysis of predictors of PVC failure.

| Variable                                         | β    | Standard error | Wald  | p     | OR   | 95% CI          |
|--------------------------------------------------|------|----------------|-------|-------|------|-----------------|
| Constant                                         | 0.453| 0.148          | 9.374 | 0.002 | 0.453|                 |
| Age                                              |      |                |       |       |      |                 |
| <=44                                             |      |                |       |       |      |                 |
| 45–59                                            | 0.258| 0.096          | 7.31  | 0.007 | 1.295| 1.074–1.561     |
| 60–74                                            | 0.318| 0.094          | 11.41 | 0.001 | 1.375| 1.143–1.654     |
| >=75                                             | 0.516| 0.108          | 22.676| 0.000 | 1.676| 1.355–2.073     |
| Department                                       |      |                |       |       |      |                 |
| Internal medicine                                |      |                |       |       |      |                 |
| Surgery                                          | 0.207| 0.074          | 7.690 | 0.006 | 1.229| 1.062–1.423     |
| Obstetrics and gynecology                        | -0.668| 0.118         | 31.892| 0.000 | 0.513| 0.407–0.647     |
| Emergency internal/surgical ward                 | 0.372| 0.150          | 6.199 | 0.013 | 1.451| 1.082–1.945     |
| History of venous puncture for nearly 1 week     |      |                |       |       |      |                 |
| No                                               |      |                |       |       |      |                 |
| Yes                                              | 0.261| 0.071          | 13.652| 0.000 | 1.298| 1.130–1.491     |
| Catheter type                                    |      |                |       |       |      |                 |
| Closed normal type                               |      |                |       |       |      |                 |
| Closed safety type                               | -0.194| 0.074         | 6.941 | 0.008 | 0.824| 0.713–0.952     |
| Opened type                                      | -1.023| 0.236         | 18.802| 0.000 | 0.359| 0.226–0.571     |
| Insertion site                                   |      |                |       |       |      |                 |
| Back of hand                                     |      |                |       |       |      |                 |
| Wrist                                            | 0.165| 0.121          | 1.862 | 0.172 | 1.179| 0.931–1.493     |
| Forearm                                          | 0.183| 0.071          | 6.657 | 0.010 | 1.201| 1.045–1.380     |
| Antecubital fossa                                | 0.061| 0.212          | 0.082 | 0.774 | 1.063| 0.702–1.608     |
| Number of puncture attempts                      |      |                |       |       |      |                 |
| <=2                                              |      |                |       |       |      |                 |
| >=2                                              | 0.276| 0.128          | 4.633 | 0.031 | 1.317| 1.025–1.693     |
| Dressing type                                    |      |                |       |       |      |                 |
| Ordinary                                         |      |                |       |       |      |                 |
| Reinforced                                       | -0.431| 0.068        | 40.755| 0.000 | 0.65 | 0.569–0.742     |
| Irritant fluid infusion                           |      |                |       |       |      |                 |
| No                                               |      |                |       |       |      |                 |
| Yes                                              | 0.296| 0.08           | 13.519| 0.000 | 1.344| 1.148–1.574     |

(Continued)
Table 3. (Continued)

| Variable                  | β     | Standard error | Wald   | p      | OR    | 95% CI       |
|---------------------------|-------|----------------|--------|--------|-------|--------------|
| Daily infusion time       |       |                |        |        |       |              |
| <4 h                      | 0.414 | 0.092          | 30.846 | 0.000  | 1.513 | 1.264–1.810  |
| 4–6 h                     | 0.625 | 0.119          | 27.535 | 0.000  | 1.868 | 1.479–2.359  |
| >6 h                      | 0.113 | 0.146          | 0.597  | 0.440  | 1.120 | 0.840–1.492  |
| Daily infusion volume     |       |                |        |        |       |              |
| ≤500                      | 0.284 | 0.093          | 9.418  | 0.002  | 1.328 | 1.108–1.592  |
| 500–1000                  | 0.209 | 0.127          | 2.703  | 0.100  | 1.232 | 0.961–1.580  |
| >1500                     | 0.113 | 0.146          | 0.597  | 0.440  | 1.120 | 0.840–1.492  |
| Sealing liquid            |       |                |        |        |       |              |
| Saline                    | 1.000 |                |        |        |       |              |
| Heparin saline            | 0.419 | 0.202          | 4.296  | 0.038  | 1.521 | 1.023–2.261  |
| Indwelling time           |       |                |        |        |       |              |
| t ≤ 24 h                  |       |                |        |        |       |              |
| 24 h < t ≤ 48 h           | −0.010| 0.116          | 0.008  | 0.929  | 0.990 | 0.789–1.241  |
| 48 h < t ≤ 72 h           | −0.093| 0.109          | 0.000  | 0.999  | 0.990 | 0.789–1.241  |
| 72 h < t ≤ 96 h           | −2.235| 0.118          | 361.555| 0.000  | 0.107 | 0.085–0.135  |
| t > 96 h                  | −2.073| 0.146          | 201.475| 0.000  | 0.126 | 0.094–0.167  |

**Figure 2.** ROC curve analysis of the prective model of PVC failure.

**Study** of adult patients scheduled for infusion therapy at one of two tertiary hospitals in Hunan China. Patients on surgery or emergency internal/surgical wards often undergo abrupt changes in their clinical status and generally receive large infusions of fluid for fluid replacement and to deliver nutritional elements and medication. Infusion of large volumes of fluid can cause vascular damage and increase vascular permeability, which may induce PVC failure.

Our study suggested that patients with a history of venous puncture in the last week were more likely to experience PVC failure. Consistent with these data, a study of patients with PVCs on the admission units and intermediate care unit of a second level regional hospital of the Principality of Asturias Health Service identified previous insertion in the same arm as a risk factor for PVC failure. Multiple catheterizations at the same site may directly damage the vascular endothelial cells at that puncture site, causing local vasoconstriction, backflow of infusion fluid to the initial venous puncture site, and leakage of fluid from the blood vessels into the surrounding tissues.

Our results revealed that use of an insertion site in the forearm increased the risk of PVC failure. In accordance with these findings, a study of adult patients admitted to various wards at King Abdulaziz Medical City, Riyadh, Saudi Arabia demonstrated that phlebitis was predicted by PVC insertion in the fore/upper arm. In contrast, the INS guidelines state that forearm insertion may prolong catheter indwelling time, relieve pain, facilitate patient self-management, and prevent unplanned removal and occlusion; however, the strength of the body of evidence supporting these practice criteria is low. Inserting a PVC in the back of the hand may improve the likelihood of a successful venous puncture at the first attempt, thus reducing vascular damage. Also in our study, repeated unsuccessful attempts at inserting catheters increased the risk of catheter failure after successful placement. Multiple or difficult catheterization attempts often result in skin or venous bruising at the insertion site and may increase the incidence of phlebitis. Furthermore, repeated catheterization can cause pain, confirming the need to improve the first-time PVC insertion success rate.

This study and others demonstrated that irritant fluid infusion and drugs such as antibiotic use, vasoactive drug use, antihemorrhagic drug use, and dexamethasone use, have an impact on PVC failure. High concentrations of
irritant fluids and drugs can increase plasma osmotic pressure, cause a fluid shift from within the vascular endothelial cells to the extracellular space, infiltration/extravasation, and vascular stiffness.

Our data suggested that prolonged duration of infusion and total daily infusion volume were risk factors for PVC failure. A previous literature review revealed that duration of infusion was a risk factor for extravasation and infiltration injuries.\(^\text{22}\) Infusing fluid for a long period of time exposes the vascular intima to forces that can cause tissue damage and an increase in vascular permeability, which can lead to infiltration/extravasation. We showed that the risk of PVC failure was increased at a total daily infusion volume of 501–1000 ml compared to a total daily infusion volume of <500 ml, a finding that is consistent with another study that reported a total daily infusion >1500 ml was a risk factor for phlebitis.\(^\text{24}\) However, we found the incidence of PVC failure did not increase when total daily infusion volume was ≥1000 ml. This may be because the body produces an adaptive response to long-term stimulation of the vascular intima by larger infusion volumes rather than the acute inflammatory response that is evoked by smaller volumes and leads to PVC failure.

Also in this study, the use of heparinized saline for tube sealing compared to normal saline was associated with an increased risk of PVC failure. In accordance with these findings, a previous study showed that increasing concentrations of heparin were associated with increasing risk of phlebitis.\(^\text{25}\) The US INS guideline\(^\text{14}\) recommend the use of preservative-free 0.9% sodium chloride solution as a tube sealing solution in adult patients. A previous prospective, controlled study in patients with gastrointestinal or liver disease compared the effects of normal saline and heparinized saline for tube sealing. Findings showed no significant differences in the incidence of occlusion or other adverse events associated with PVCs in patients who received either normal saline or heparin saline.\(^\text{26}\)

Based the results of the present study, we recommend that healthcare providers receive practical training on the venipuncture technique, avoid repeat puncture at the same insertion site, and avoid puncture sites that are associated with the risk of PVC failure. In particular, the site of PVC placement in elderly surgical patients should be continuously monitored for early detection of PVC failure. Healthcare providers should have a list of drugs classified as irritants or vesicants so they can monitor patients receiving fluid infusions containing these drugs more frequently. Continuous PVC failures may result in the wrong dose of drug being delivered at the wrong time and vein wasting. An alternative device such as a mini midline, a midline, or a peripherally inserted central catheter (PICC) should be considered for patients receiving large infusions over an extended period of time or irritants or vesicants. Healthcare providers may consider using a vascular access management tool, such as the UK Vessel Health and Preservation (VHP) framework\(^\text{27}\) or the I-DECIDE clinical decision-making tool,\(^\text{28}\) for device selection and replacement or removal of a device.

Our data also showed that department (Obstetrics and Gynecology), catheter type (closed safety and open PVC), reinforced dressing, and indwelling period 48 h < t ≤ 72 h, 72 h < t ≤ 96 h, t > 96 h were independent predictors of PVC success. In this study, patients in the department of Obstetrics and Gynecology had a lower incidence of catheter failure compared to patients in other departments, possibly because patients in the department of Obstetrics and Gynecology require less intravenous fluids and are less likely to receive drugs due to concerns about fetal safety.\(^\text{20}\) With regard to catheter type, in contrast to our findings, a randomized control trial conducted in adult patients requiring a PVC on three medical and surgical wards at the Hospital Clínico San Carlos showed a 29% reduction in the incidence of phlebitis with closed safety versus open PVCs,\(^\text{29}\) while a second randomized trial confirmed that closed PVC systems are safer and more economical than open systems.\(^\text{30}\) Further research is required to understand the reasons behind these disparate results. With regard to reinforced dressing, the previous study in adult patients requiring a PVC in the medical and surgical wards of a tertiary hospital located in Queensland, Australia found no significant difference in the effect of reinforced dressings and ordinary dressings on the incidence of phlebitis.\(^\text{16}\) It is likely that a catheter that is not fixed properly may move in the blood vessel, damage vascular tissue, and cause complications.\(^\text{31}\) The discrepancy between the previous study and our findings may be resolved by additional investigations. With regard to indwelling period 48 h < t ≤ 72 h, 72 h < t ≤ 96 h, and t > 96 h, the previous study in adult patients scheduled for infusion therapy at one of two tertiary hospitals in Hunan China showed median dwell time to catheter failure was 52 h (interquartile range: 36–73 h), the incidence rate of catheter failure significantly increased by 1.1%/h in the first 38 h after catheter insertion, the incidence rate was significantly decreased from 39 to 149 h, and at >149 h, there was no significant change in the incidence rate.\(^\text{20}\) In the present study the incidence of PVC failure decreased at >48h, possibly because the body mounted an adaptive response to the catheter as indwell time increased.

Limitations
This study was limited as it did not consider the healthcare providers’ experience with the venipuncture technique and special consideration was not given to patients receiving infusions containing drugs classified as irritants or vesicants, which should be explored in future studies.

Conclusion
This study should raise awareness among healthcare providers of the risk factors for PVC failure, including older
age, hospitalization on the surgery or emergency/internal/surgical ward, history of venous puncture in the last week, forearm insertion site, ≥2 puncture attempts, irritant fluid infusion, daily infusion time >4 h, daily infusion volume 501–1000 mL, and use of heparinized saline as the sealing liquid. Healthcare providers should use vascular access device selection tools that consider type of device, the nature and amount of the infusion, and the duration of the infusion to select a clinically appropriate device. During catheter indwelling, evaluation tools should be applied for the timely detection of complications. Healthcare providers should have a list of drugs classified as irritants or vesicants so they can monitor patients receiving fluid infusions containing these drugs more frequently.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval
This study was approved by the Medical Ethics Committee of The First Affiliated Hospital of Soochow University in 2018 (approval number: No.135) and registered with the Chinese Clinical Trial Registration Center (ChiCTR1800019714).

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Suzhou Science and Technology Development Plan Project.

ORCID ID
Yi-qun Yang https://orcid.org/0000-0001-6052-4162

References
1. Webster J, Osborne S, Rickard CM, et al. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev 2019; 1: CD007798.
2. Guo JY, Yang J, Zhou Y, et al. Development of the short peripheral venous catheter in infusion therapy. Chin J Nurs 2015; 50: 1240–1244.
3. Wallis MC, McGrail M, Webster J, et al. Risk factors for peripheral intravenous catheter failure: a multivariate analysis of data from a randomized controlled trial. Infect Control Hosp Epidemiol 2014; 35: 63–68.
4. Alexandrou E, Ray-Barruel G, Carr PJ, et al. International prevalence of the use of peripheral intravenous catheters. J Hosp Med 2015; 10: 530–533.
5. Keogh S, Flynn J, Marsh N, et al. Varied flushing frequency and volume to prevent peripheral intravenous catheter failure: a pilot, factorial randomised controlled trial in adult medical-surgical hospital patients. Trials 2016; 17: 348.
6. Helm RE, Klausner JD, Klemperer JD, et al. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs 2019; 42: 151–164.
7. Rickard CM, Webster J, Wallis MC, et al. Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet 2012; 380: 1066–1074.
8. Alexandrou E, Ray-Barruel G, Carr PJ, et al. Use of short peripheral intravenous catheters: characteristics, management, and outcomes worldwide. J Hosp Med 2018; 13: E1–E7.
9. Carr PJ, Rippey JCR, Cooke ML, et al. Factors associated with peripheral intravenous cannulation first-time insertion success in the emergency department. A multicentre prospective cohort analysis of patient, clinician and product characteristics. BMJ Open 2019; 9: e022278.
10. Carr PJ, Rippey JCR, Cooke ML, et al. From insertion to removal: a multicenter survival analysis of an admitted cohort with peripheral intravenous catheters inserted in the emergency department. Infect Control Hosp Epidemiol 2018; 39: 1216–1221.
11. Abolfotouh MA, Salam M, Bani-Mustafa A, et al. Prospective study of incidence and predictors of peripheral intravenous catheter-induced complications. Ther Clin Risk Manag 2014; 10: 993–1001.
12. Ciccolini G, Manzoli L, Simonetti V, et al. Phlebitis risk varies by peripheral venous catheter site and increases after 96 hours: a large multi-centre prospective study. J Adv Nurs 2014; 70: 2539–2549.
13. Atay S, Sen S and Cukurdu L. Phlebitis-related peripheral venous catheterization and the associated risk factors. Niger J Clin Pract 2018; 21: 827–831.
14. Gorski LA. The 2016 infusion therapy standards of practice. Home Healthc Now 2017; 35: E1–E2.
15. Hadaway L. Infiltration and extravasation. Preventing a complication of IV catheterization. Am J Nurs 2007; 107: 64–72.
16. Marsh N, Webster J, Larson E, et al. Observational study of peripheral intravenous catheter outcomes in adult hospitalized patients: a multivariable analysis of peripheral intravenous catheter failure. J Hosp Med 2018; 13: 83–89.
17. Simin D, Milutinović D, Turkulov V, et al. Incidence, severity and risk factors of peripheral intravenous cannula-induced complications: an observational prospective study. J Clin Nurs 2019; 28: 1585–1599.
18. Palese A, Ambrosi E, Fabris F, et al. Nursing care as a predictor of phlebitis related to insertion of a peripheral venous cannula in emergency departments: findings from a prospective study. J Hosp Infect 2016; 92: 280–286.
19. Ray-Barruel G, Polit DF, Murfield JE, et al. Infusion phlebitis assessment measures: a systematic review. J Eval Clin Pract 2014; 20: 191–202.
20. Wei T, Li X, Yue Z, et al. Catheter dwell time and risk of catheter failure in adult patients with peripheral venous catheters. J Clin Nurs 2019; 28: 4488–4495.
21. Fernández-García C, Mata-Peón E and Avanzas-Fernández S. Related factors with extravasation of non-cytostatic agents in peripheral vein catheters. Enferm Clin 2017; 27: 71–78.
22. Reynolds PM, MacLaren R, Mueller SW, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy 2014; 34: 617–632.
23. Dillon MF, Curran J, Martos R, et al. Factors that affect longevity of intravenous cannulas: a prospective study. QJM 2008; 101: 731–735.
24. Hu MM, Gu P, Chen L, et al. Cox regression model for risk factors of catheter-related superficial peripheral phlebitis of patients in neurological department. *J Nurs* 2016; 23: 5–8.

25. Zhang L, Wang H, Zhou Y, et al. Effect of three different flush solutions to flush out the peripheral intravenous catheters on phlebitis and catheter blockage. *J Nurs Sci* 2013; 28: 47–48.

26. Wang R, Luo O, He L, et al. Preservative-free 0.9% sodium chloride for flushing and locking peripheral intravenous access device: a prospective controlled trial. *J Evid Based Med* 2012; 5: 205–208.

27. Hallam C, Weston V, Denton A, et al. Development of the UK Vessel Health and Preservation (VHP) framework: a multi-organisational collaborative. *J Infect Prev* 2016; 17: 65–72.

28. Ray-Barruel G, Cooke M, Chopra V, et al. The I-DECIDED clinical decision-making tool for peripheral intravenous catheter assessment and safe removal: a clinimetric evaluation. *BMJ Open* 2020; 10: e035239.

29. González López JL, Arribi Vilela A, Fernández del Palacio E, et al. Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. *J Hosp Infect* 2014; 86: 117–126.

30. Galang H, Hubbard-Wright C, Hahn DS, et al. A randomized trial comparing outcomes of 3 types of peripheral intravenous catheters. *J Nurs Care Qual* 2020; 35: 6–12.

31. Kaur P, Thakur R, Kaur S, et al. Assessment of risk factors of phlebitis amongst intravenous cannulated patients. *Nurs Midwifery Res J* 2011; 7: 106–114.